# US 2024/0189313 A1 · Solid dispersions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0189313 A1
- Document ID: US20240189313A1
- Status: Published application
- Kind: A1
- Application number: 18/281,051
- Filed: 2022-03-11
- Published: 2024-06-13
- Earliest claimed: 2021-03-11
- Assignees: Inventisbio Co., Ltd.
- Applicants: InventisBio Co., Ltd.
- Inventors: Xing DAI; Xiaomei WANG; Yanqin LIU; Yueheng JIANG; Yaolin WANG
- Web page: https://patentgrep.com/patent/US20240189313A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61K 9/0056: {Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals}
- A61K 9/10: Dispersions; Emulsions
- A61K 9/146: {with organic macromolecular compounds}
- A61K 9/1682: {Processes}
- A61K 9/4866: {Organic macromolecular compounds}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- C07D 471/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Provided herein are solid dispersions and pharmaceutical compositions of Compound 1. Also provided are methods of treating a disease or disorder such as a cancer or infectious disease that comprises administering to a subject in need thereof the solid dispersions or compositions described herein.

## Claims

### Claim 1

A solid dispersion comprising Compound 1 in an amorphous form and a matrix polymer, wherein Compound 1 has the following formula:

### Claim 2 (depends on 1)

The solid dispersion of claim 1, which is essentially free of Compound 1 in a crystalline form.

### Claim 3 (depends on 1)

The solid dispersion of claim 1, which does not include Compound 1 in a crystalline form in an amount detectable by XRPD.

### Claim 4 (depends on 1, 2, 3)

The solid dispersion of any one of claims 1-3, wherein the matrix polymer comprises one or more polymers selected from hydrophilic polymers, hydrophobic polymers, and amphiphilic polymers.

### Claim 5 (depends on 1, 2, 3)

The solid dispersion of any one of claims 1-3, wherein the matrix polymer comprises an acrylate based polymer, such as a polyacrylate or polymethacrylate, such as a cationic acrylate based copolymer.

### Claim 6 (depends on 1, 2, 3)

The solid dispersion of any one of claims 1-3, wherein the matrix polymer comprises a copolymer based on monomers comprising aminoalkyl acrylate and alkyl acrylate.

### Claim 7 (depends on 1, 2, 3)

The solid dispersion of any one of claims 1-3, wherein the matrix polymer comprises a copolymer based on monomers comprising aminoalkyl methacrylate and alkyl methacrylate.

### Claim 8 (depends on 1, 2, 3)

The solid dispersion of any one of claims 1-3, wherein the matrix polymer comprises a copolymer based on monomers comprising 2-dimethylaminoethyl methacrylate and an alkyl methacrylate.

### Claim 9 (depends on 1, 2, 3)

The solid dispersion of any one of claims 1-3, wherein the matrix polymer comprises a copolymer based on monomers comprising 2-dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate.

### Claim 10 (depends on 9)

The solid dispersion of claim 9, wherein the copolymer is based on monomers comprising 2-dimethylaminoethyl methacrylate, butyl methacrylate, and methyl methacrylate with a ratio of about 2:1:1.

### Claim 11 (depends on 6, 7, 8, 9, 10)

The solid dispersion of any one of claims 6-10, wherein the copolymer is a random copolymer.

### Claim 12 (depends on 9, 10)

The solid dispersion of claim 9 or 10, wherein the wherein the matrix polymer is poly((2-dimethylaminoethyl)methacrylate, butyl methacrylate, methyl methacrylate) (2:1:1) (e.g., Eudragit®E100).

### Claim 13 (depends on 1, 2, 3)

The solid dispersion of any one of claims 1-3, wherein the matrix polymer comprises an N-vinyl lactam polymer, such as one or more polymers selected from vinyl pyrrolidone polymers and vinyl caprolactam polymers.

### Claim 14 (depends on 1, 2, 3)

The solid dispersion of any one of claims 1-3, wherein the matrix polymer comprises one or more polymers selected from povidone, copovidone, and a graft copolymer of polyethylene glycol, polyvinyl acetate and polyvinylcaprolactam.

### Claim 15 (depends on 1, 2, 3)

The solid dispersion of any one of claims 1-3, wherein the matrix polymer comprises a graft copolymer of polyethylene glycol 6000, polyvinyl acetate and polyvinylcaprolactam, with a weight average molecular weight (Mw) of about 90,000 g/mol to about 140,000 g/mol, such as about 118,000 g/mol.

### Claim 16 (depends on 1, 2, 3)

The solid dispersion of any one of claims 1-3, wherein the matrix polymer comprises a graft copolymer of polyethylene glycol 6000, polyvinyl acetate and polyvinylcaprolactam, with a weight ratio of about 13:30:57, wherein the graft copolymer has a weight average molecular weight (Mw) of about 118,000 g/mol.

### Claim 17 (depends on 1, 2, 3)

The solid dispersion of any one of claims 1-3, wherein the matrix polymer comprises one or more cellulose selected from hydroxypropylmethyl cellulose, hydroxypropylmethyl cellulose acetate succinate, hydroxypropyl methylcellulose phthalate (HPMCP), and hydroxypropyl cellulose.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The solid dispersion of any one of claims 1-17, wherein the weight ratio of Compound 1 to the matrix polymer ranges from about 1:50 to 10:1, such as about 1:20, about 1:10, about 1:4, about 1:2, about 2:3, about 1:1, about 3:2, about 10:1, or any range between the recited values.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The solid dispersion of any one of claims 1-18, wherein Compound 1 is present in the solid dispersion in an amount ranging from about 10-80% by weight, such as about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, or any range between the recited values.

### Claim 20

A process for making a solid dispersion comprising:
(a) mixing Compound 1, a polymer, and a solvent to form a solution; and
(b) spray-drying the solution of step (a), thereby obtaining the solid dispersion,
wherein Compound 1 has the following formula:

### Claim 21 (depends on 20)

The process of claim 20, wherein the solvent comprises acetone, dichloromethane ethanol, methanol, water or a mixture thereof.

### Claim 22 (depends on 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 20, 21)

The process of claim 20 or 21, wherein the polymer is any of the polymers defined in claims 4-17.

### Claim 23 (depends on 20, 21, 22)

The process of any one of claims 20-22, wherein the weight ratio of Compound 1 to the polymer ranges from about 1:50 to 10:1, such as about 1:20, about 1:10, about 1:4, about 1:2, about 2:3, about 1:1, about 3:2, about 10:1, or any range between the recited values.

### Claim 24 (depends on 20, 21, 22, 23)

The process of any one of claims 20-23, wherein the solid dispersion comprises Compound 1 in an amount ranging from about 10-80% by weight, such as about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, or any range between the recited values.

### Claim 25 (depends on 20, 21, 22, 23, 24)

The solid dispersion prepared by the process according to any one of claims 20-24.

### Claim 26 (depends on 25)

The solid dispersion of claim 25, which is essentially free of Compound 1 in a crystalline form.

### Claim 27 (depends on 25)

The solid dispersion of claim 25, which does not include Compound 1 in a crystalline form in an amount detectable by XRPD.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 25, 26, 27)

The solid dispersion of any one of claims 1-19 and 25-27, which is storage stable, for example, the solid dispersion is characterized in that, upon storage at 25° C. and 60% relative humidity or 40° C. and 75% relative humidity for one week or longer, such as up to 6 months or longer, the solid dispersion does not have Compound 1 in a crystalline form in an amount detectable by XRPD.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 25, 26, 27, 28)

A pharmaceutical composition comprising the solid dispersion of any one of claims 1-19 and 25-28.

### Claim 30 (depends on 29)

The pharmaceutical composition of claim 29, wherein the solid dispersion is present in an amount ranging from about 10-90% by weight, such as about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, or any range between the recited values.

### Claim 31 (depends on 29, 30)

The pharmaceutical composition of claim 29 or 30, wherein the solid dispersion is present in an amount ranging from about 50-70% by weight, such as about 50%, about 60%, about 70%, or any range between the recited values.

### Claim 32 (depends on 29, 30, 31)

The pharmaceutical composition of any one of claims 29-31, which is essentially free of Compound 1 in a crystalline form.

### Claim 33 (depends on 29, 30, 31)

The pharmaceutical composition of any one of claims 29-31, which does not include Compound 1 in a crystalline form in an amount detectable by XRPD.

### Claim 34 (depends on 29, 30, 31, 32, 33)

The pharmaceutical composition of any one of claims 29-33, further comprising one or more additional pharmaceutical excipients.

### Claim 35 (depends on 34)

The pharmaceutical composition of claim 34, wherein the one or more additional pharmaceutical excipients are selected from a diluent (e.g., microcrystalline cellulose, lactose, mannitol, etc.), a disintegrant (e.g., croscarmellose sodium, crospovidone, pregelatinized starch, etc.), a glidant (e.g., colloidal silica dioxide), a lubricant (e.g., sodium stearyl fumarate, magnesium stearate, hydrogenated castor oil, etc.), a surfactant (e.g., sodium lauryl sulfate, poloxamers, etc.), and a coating material.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 25, 26, 27, 28)

A method of preparing a pharmaceutical composition comprising mixing the solid dispersion according to any one of claims 1-19 and 25-28 with a pharmaceutical excipient.

### Claim 37 (depends on 36)

The method of claim 36, wherein the pharmaceutical excipient comprises one or more excipients selected from a diluent (e.g., microcrystalline cellulose, lactose, mannitol, etc.), a disintegrant (e.g., croscarmellose sodium, crospovidone, pregelatinized starch, etc.), a glidant (e.g., colloidal silica dioxide), a lubricant (e.g., sodium stearyl fumarate, magnesium stearate, hydrogenated castor oil, etc.), a surfactant (e.g., sodium lauryl sulfate, poloxamers, etc.), and a coating material.

### Claim 38 (depends on 36, 37)

The method of claim 36 or 37, wherein the pharmaceutical composition comprises the solid dispersion in an amount ranging from about 10-90% by weight, such as about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, or any range between the recited values.

### Claim 39 (depends on 36, 37)

The method of claim 36 or 37, wherein the pharmaceutical composition comprises the solid dispersion in an amount ranging from about 50-70% by weight, such as about 50%, about 60%, about 70%, or any range between the recited values.

### Claim 40 (depends on 36, 37, 38, 39)

The pharmaceutical composition produced by the method according to any one of claims 36-39.

### Claim 41 (depends on 29, 30, 31, 32, 33, 34, 35, 40)

The pharmaceutical composition of any one of claims 29-35 and 40, which is an oral dosage form.

### Claim 42 (depends on 29, 30, 31, 32, 33, 34, 35, 40, 41)

The pharmaceutical composition of any one of claims 29-35 and 40-41, which is in the form of a capsule, such as a hard gelatin capsule, a tablet, a strip, a caplet, a sachet, a lozenge, a suspension, or a powder for suspension.

### Claim 43 (depends on 29, 30, 31, 32, 33, 34, 35, 40, 41, 42)

The pharmaceutical composition of any one of claims 29-35 and 40-42, which is storage stable.

### Claim 44 (depends on 29, 30, 31, 32, 33, 34, 35, 40, 41, 42, 43)

The pharmaceutical composition of any one of claims 29-35 and 40-43, characterized in that, upon storage at 25° C. and 60% relative humidity or 40° C. and 75% relative humidity for one week or longer, such as up to 6 months or longer, the pharmaceutical composition does not have Compound 1 in a crystalline form in an amount detectable by XRPD.

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 40, 41, 42, 43, 44)

A method of treating cancer in a subject, the method comprising administering to the subject a therapeutically effective amount of the solid dispersion of any one of claims 1-19 and 25-28 or the pharmaceutical composition of any one of claims 29-35 and 40-44.

### Claim 46 (depends on 45)

The method of claim 45, wherein the cancer is a hematologic malignancy, lung cancer (e.g., non-small cell lung cancer), pancreatic cancer, endometrial cancer, gall bladder cancer, thyroid cancer, bile duct cancer, and/or colorectal cancer.

### Claim 47 (depends on 45, 46)

The method of claim 45 or 46, further comprising treating the subject with an additional therapy.

### Claim 48 (depends on 47)

The method of claim 47, wherein the additional therapy comprises administering to the subject a chemotherapeutic agent, therapeutic antibody, radiation, cell therapy, and/or immunotherapy.

### Claim 49 (depends on 45, 46, 47, 48)

The method of any one of claims 45-48, wherein the subject has a G12C mutation of KRAS, HRAS and/or NRAS.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 40, 41, 42, 43, 44)

A method of inhibiting KRAS G12C mutant protein in a cell of a subject, the method comprising administering to the subject an effective amount of the solid dispersion of any one of claims 1-19 and 25-28 or the pharmaceutical composition of any one of claims 29-35 and 40-44.
